Literature DB >> 27188181

Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.

Ersilia M DeFilippis1, Michael M Givertz2,3.   

Abstract

Over the past two decades, therapeutics for diabetes have evolved from drugs with known heart failure risk to classes with potential benefit for patients with heart failure. As many as 25 to 35 % of patients with heart failure carry a diagnosis of type 2 diabetes mellitus. Therefore, newer drug classes including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GIP-1) agonists, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors are being examined for cardiovascular safety as well as their effects on left ventricular function, quality of life, and other measures of disease progression. The purpose of this review is to summarize the existing evidence on these classes of anti-diabetic agents in patients with heart failure.

Entities:  

Keywords:  Diabetes; Dipeptidyl peptidase 4 inhibitor; Glucagon-like peptide 1 agonist; Heart failure; Insulin resistance; Sodium-glucose cotransporter 2 inhibitor

Mesh：

Substances：

Year:  2016        PMID： 27188181     DOI： 10.1007/s11897-016-0291-y

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  69 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.

Authors:  R R Henry; J B Buse; H Wu; L Durrwell; R Mingrino; K Jaekel; B El Azzouzi; M Andjelkovic; M Herz
Journal:  Diabetes Obes Metab       Date:  2015-04-08       Impact factor: 6.577

4.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

Review 5.  Incretin-related drug therapy in heart failure.

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2015-02

6.  Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure.

Authors:  Wei-Ming Huang; Pai-Feng Hsu; Hao-Min Cheng; Dai-Yin Lu; Yu-Lun Cheng; Chao-Yu Guo; Shih-Hsien Sung; Wen-Chung Yu; Chen-Huan Chen
Journal:  Circ J       Date:  2015-11-20       Impact factor: 2.993

7.  Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.

Authors:  Erin E Mulvihill; Elodie M Varin; John R Ussher; Jonathan E Campbell; K W Annie Bang; Tahmid Abdullah; Laurie L Baggio; Daniel J Drucker
Journal:  Diabetes       Date:  2015-12-15       Impact factor: 9.461

8.  Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.

Authors:  Carlo B Giorda; Roberta Picariello; Barbara Tartaglino; Lisa Marafetti; Fabiana Di Noi; Annalisa Alessiato; Giuseppe Costa; Roberto Gnavi
Journal:  BMJ Open       Date:  2015-06-05       Impact factor: 2.692

9.  Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

Authors:  M J Davies; A Trujillo; U Vijapurkar; C V Damaraju; G Meininger
Journal:  Diabetes Obes Metab       Date:  2015-02-15       Impact factor: 6.577

10.  Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Authors:  Meghan Sauvé; Kiwon Ban; M Abdul Momen; Yu-Qing Zhou; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2010-01-22       Impact factor: 9.461
View more
  1 in total

Review 1.  Understanding the role of the gut ecosystem in diabetes mellitus.

Authors:  Wanping Aw; Shinji Fukuda
Journal:  J Diabetes Investig       Date:  2017-05-24       Impact factor: 4.232
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.